This report aims to provide detailed insights into the global Vaccines Market. It provides valuable information on the type, procedure, application, and region in the market. Furthermore, the information for these segments, by region, is also presented in this report. Leading players in the market are profiled to study their product offerings and understand the strategies undertaken by them to be competitive in this market.
Expected Revenue Growth:
The global vaccines market (including COVID-19 vaccines) is projected to reach USD 149.2 billion by 2026 from USD 139.4 billion in 2021 during the forecast period. The global vaccines market (excluding COVID-19 vaccines) is projected to reach USD 67.2 billion by 2026 from USD 41.4 billion in 2021, at a CAGR of 10.2% from 2021 to 2026.
Market growth is largely driven by the rise of emerging and re-emerging infectious diseases, increasing company initiatives to enhance vaccine R&D, growing government support for vaccine development, and the rising focus on immunization. However, the huge capital investments required for developing vaccines and low purchasing power in developing countries may restrain the market growth.
Download PDF Brochure:
Conjugate vaccines segment accounted for the largest share of the technology segment (excluding COVID 19 vaccines)
Based on technology, the vaccines market (excluding COVID 19 vaccines) has been segmented into conjugate vaccines, recombinant vaccines, inactivated & subunit vaccines, live attenuated vaccines, toxoid vaccines, and other vaccines such as mRNA vaccines, DNA vaccines, and viral vector vaccines. The conjugate vaccines segment accounted for the largest share of the global vaccines market (excluding COVID-19 vaccines), by technology, in 2020. The large share of this segment can be attributed to the increasing government support and rising company investments in conjugate vaccine development.
The Pneumococcal disease segment accounted for the largest share in 2020
Based on disease indication, the vaccines market is segmented into pneumococcal disease, influenza, combination vaccines, HPV, meningococcal disease, herpes zoster, rotavirus, MMR, varicella, hepatitis, DTP, polio, COVID-19, and other disease indications. The pneumococcal disease segment accounted for the largest share of the vaccines market, by disease indication, in 2020. The large share of this segment is attributed to the high incidence of pneumococcal disease and increasing government investments in pneumococcal vaccination programs.
Monovalent vaccines segment accounted for the largest share of the type segment
Based on type, the global vaccines market is segmented into monovalent and multivalent vaccines. The monovalent vaccines segment accounted for the largest share of the global vaccines market (excluding COVID-19 vaccines) in 2020. Growing disease prevalence has prompted initiatives for immunization against specific infectious diseases such as COVID 19. This has led to a large market share for monovalent vaccines Rising prevalence of emerging and re-emerging infectious diseases and R&D initiatives will contrive to drive the market for monovalent vaccines.
Pediatric vaccines segment accounted for the largest share of the end user segment
Based on end user, the global vaccines market is segmented into pediatric and adult users. In 2020, the pediatric users segment accounted for the largest share of the vaccines market (excluding COVID 19 vaccines), while the adult user segment is estimated to register the highest CAGR during the forecast period. Increased initiatives from government and non-government organizations and increasing company initiatives to develop advanced pediatric vaccines for preventing diseases are expected to drive market growth for pediatric vaccines.
Intramuscular & Subcutaneous route of administration segment accounted for the largest share of the route of administration segment
Based on the route of administration, the vaccines market is segmented into intramuscular and subcutaneous administration, oral administration, and other routes of administration. In 2020, the intramuscular and subcutaneous administration segment accounted for the largest share of the vaccines market (excluding COVID-19 vaccines). Intramuscular & Subcutaneous is one of the most prevalent route of administration for vaccines due to its precise control of dose and administration rate, rapid exposure to antigen, and ease of administration.
North America was the largest regional market for Vaccines market in 2020.
Based on the region, the vaccines market is broadly segmented into North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. North America accounted for the largest share of the vaccines market in 2020. The high prevalence of infectious diseases, increasing investments by government organizations for vaccine development, increasing R&D investments by market players, and mandatory reporting are some of the key factors driving the vaccines market in North America.
Request Sample Report:
Key Market Players
Key players operating in the global vaccines market include GlaxoSmithKline Plc (UK), Merck & Co., Inc. (US), Sanofi SA (France), and Pfizer, Inc. (US).
MarketsandMarkets™ provides quantified B2B research on 30,000 high growth niche opportunities/threats which will impact 70% to 80% of worldwide companies’ revenues. Currently servicing 7500 customers worldwide including 80% of global Fortune 1000 companies as clients. Almost 75,000 top officers across eight industries worldwide approach MarketsandMarkets™ for their painpoints around revenues decisions.
Our 850 fulltime analyst and SMEs at MarketsandMarkets™ are tracking global high growth markets following the "Growth Engagement Model – GEM". The GEM aims at proactive collaboration with the clients to identify new opportunities, identify most important customers, write "Attack, avoid and defend" strategies, identify sources of incremental revenues for both the company and its competitors. MarketsandMarkets™ now coming up with 1,500 MicroQuadrants (Positioning top players across leaders, emerging companies, innovators, strategic players) annually in high growth emerging segments. MarketsandMarkets™ is determined to benefit more than 10,000 companies this year for their revenue planning and help them take their innovations/disruptions early to the market by providing them research ahead of the curve.
MarketsandMarkets’s flagship competitive intelligence and market research platform, "Knowledgestore" connects over 200,000 markets and entire value chains for deeper understanding of the unmet insights along with market sizing and forecasts of niche markets.
Mr. Aashish Mehra
630 Dundee Road
Northbrook, IL 60062
USA : 1-888-600-6441